Spectrum Wealth Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

Spectrum Wealth Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$120K	Hold	247	–	–	0.01%	139
2024 Q4	$99.5K	Hold	247	–	–	0.01%	151
2024 Q3	$115K	Sell	247 -73	-23%	-$35.1K	0.01%	144
2024 Q2	$150K	Sell	320 -5,881	-95%	-$2.55M	0.02%	137
2024 Q1	$2.59M	Sell	6,201 -42	-0.7%	-$17.8K	0.32%	67
2023 Q4	$2.54M	Buy	+6,243	New	+$2.31M	0.35%	66

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Spectrum Wealth Counsel's VRTX Position: Q1 2025 in Review

Spectrum Wealth Counsel held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2025 at 247 shares worth $120K. The position accounts for 0.01% of the portfolio, ranked #139.

Spectrum Wealth Counsel first reported a position in VRTX in Q4 2023 and has held it in 6 quarters since. The position peaked at $2.59M in Q1 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Spectrum Wealth Counsel held 247 shares of Vertex Pharmaceuticals worth $120K as of Q1 2025.
Spectrum Wealth Counsel left its Vertex Pharmaceuticals share count unchanged in Q1 2025.
Vertex Pharmaceuticals made up 0.01% of Spectrum Wealth Counsel's portfolio in Q1 2025, its #139 holding.
Spectrum Wealth Counsel first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
Spectrum Wealth Counsel's Vertex Pharmaceuticals position peaked at $2.59M in Q1 2024.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Spectrum Wealth Counsel's 13F filing for Q1 2025, filed 7 May 2025.